Vaccine Research and Development Center
DEJIMA Infectious Disease Research Alliance
Nagasaki University

Contact
  • Vaccine development research newly started in Nagasaki,
    the birthplace of vaccines in Japan.
Topics
View all
About us
Vaccine Research and Development Center (VRDC), DEJIMA Infectious Disease Research Alliance (DIDA), Nagasaki University is one of the four synergistic centers selected for the Project 'Japan Initiative for World-leading Vaccine Research and Development Centers'. It aims to promote the development of vaccines against highly pathogenic and tropical pathogens that have been studied by Nagasaki University and to develop vaccines against infectious diseases that pose a threat to mankind.
Careers

  • There is no registered post.

Publications
12924226 1 apa 5 default desc year 1 115 https://dida.nagasaki-u.ac.jp/dida_wp/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22L2BX6J4I%22%2C%22library%22%3A%7B%22id%22%3A12924226%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Yoshikawa%20et%20al.%22%2C%22parsedDate%22%3A%222025-12-19%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BYoshikawa%2C%20R.%2C%20Ishii%2C%20Y.%2C%20Sano%2C%20N.%2C%20%26amp%3B%20Yasuda%2C%20J.%20%282025%29.%20Remdesivir%20as%20a%20potent%20antiviral%20against%20prototype%20and%20current%20epidemic%20Oropouche%20virus%20strains%20%28BeAn19991%20and%20PE-IAM4637%29.%20%26lt%3Bi%26gt%3BVirus%20Research%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B363%26lt%3B%5C%2Fi%26gt%3B%2C%20199680.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.virusres.2025.199680%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.virusres.2025.199680%26lt%3B%5C%2Fa%26gt%3B%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Remdesivir%20as%20a%20potent%20antiviral%20against%20prototype%20and%20current%20epidemic%20Oropouche%20virus%20strains%20%28BeAn19991%20and%20PE-IAM4637%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rokusuke%22%2C%22lastName%22%3A%22Yoshikawa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yoshiyasu%22%2C%22lastName%22%3A%22Ishii%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Naomi%22%2C%22lastName%22%3A%22Sano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jiro%22%2C%22lastName%22%3A%22Yasuda%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222025-12-19%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.virusres.2025.199680%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS0168170225001583%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%2201681702%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222026-02-04T02%3A41%3A49Z%22%7D%7D%2C%7B%22key%22%3A%224AXCQFSL%22%2C%22library%22%3A%7B%22id%22%3A12924226%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sakurai%20et%20al.%22%2C%22parsedDate%22%3A%222026-01-08%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BSakurai%2C%20Y.%2C%20Hirano%2C%20M.%2C%20Okada%2C%20S.%2C%20Kurosaki%2C%20Y.%2C%20Yoshikawa%2C%20R.%2C%20Barr%2C%20J.%20N.%2C%20Hewson%2C%20R.%2C%20Yoshii%2C%20K.%2C%20%26amp%3B%20Yasuda%2C%20J.%20%282026%29.%20Identification%20of%20claramine%20and%20anidulafungin%20as%20entry%20inhibitors%20of%20Crimean%26%23x2013%3BCongo%20hemorrhagic%20fever%20virus.%20%26lt%3Bi%26gt%3BAntiviral%20Research%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B246%26lt%3B%5C%2Fi%26gt%3B%2C%20106343.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.antiviral.2026.106343%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.antiviral.2026.106343%26lt%3B%5C%2Fa%26gt%3B%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Identification%20of%20claramine%20and%20anidulafungin%20as%20entry%20inhibitors%20of%20Crimean%5Cu2013Congo%20hemorrhagic%20fever%20virus%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yasuteru%22%2C%22lastName%22%3A%22Sakurai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Minato%22%2C%22lastName%22%3A%22Hirano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sayaka%22%2C%22lastName%22%3A%22Okada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yohei%22%2C%22lastName%22%3A%22Kurosaki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rokusuke%22%2C%22lastName%22%3A%22Yoshikawa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20N.%22%2C%22lastName%22%3A%22Barr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roger%22%2C%22lastName%22%3A%22Hewson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kentaro%22%2C%22lastName%22%3A%22Yoshii%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jiro%22%2C%22lastName%22%3A%22Yasuda%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222026-01-08%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.antiviral.2026.106343%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS0166354226000021%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%2201663542%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222026-02-04T02%3A40%3A53Z%22%7D%7D%2C%7B%22key%22%3A%22RL6MAPUX%22%2C%22library%22%3A%7B%22id%22%3A12924226%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mogasale%20et%20al.%22%2C%22parsedDate%22%3A%222026-01-07%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMogasale%2C%20V.%20V.%2C%20John%2C%20J.%2C%20Sahai%2C%20N.%2C%20Ray%2C%20A.%2C%20Farooqui%2C%20H.%20H.%2C%20Mogasale%2C%20V.%2C%20Dhoubhadel%2C%20B.%20G.%2C%20Edmunds%2C%20W.%20J.%2C%20Clark%2C%20A.%2C%20%26amp%3B%20Abbas%2C%20K.%20%282026%29.%20Burden%20of%20typhoid%20fever%20and%20antimicrobial%20resistance%20in%20India%20%282023%29%3A%20a%20modelling%20study.%20%26lt%3Bi%26gt%3BThe%20Lancet%20Regional%20Health%20-%20Southeast%20Asia%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B44%26lt%3B%5C%2Fi%26gt%3B%2C%20100714.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lansea.2025.100714%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lansea.2025.100714%26lt%3B%5C%2Fa%26gt%3B%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Burden%20of%20typhoid%20fever%20and%20antimicrobial%20resistance%20in%20India%20%282023%29%3A%20a%20modelling%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vijayalaxmi%20V.%22%2C%22lastName%22%3A%22Mogasale%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacob%22%2C%22lastName%22%3A%22John%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nikhil%22%2C%22lastName%22%3A%22Sahai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arindam%22%2C%22lastName%22%3A%22Ray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Habib%20Hasan%22%2C%22lastName%22%3A%22Farooqui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vittal%22%2C%22lastName%22%3A%22Mogasale%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bhim%20Gopal%22%2C%22lastName%22%3A%22Dhoubhadel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20John%22%2C%22lastName%22%3A%22Edmunds%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Clark%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kaja%22%2C%22lastName%22%3A%22Abbas%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222026-01-07%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.lansea.2025.100714%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS2772368225001854%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%2227723682%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222026-02-04T02%3A40%3A17Z%22%7D%7D%2C%7B%22key%22%3A%22N7TLAKW3%22%2C%22library%22%3A%7B%22id%22%3A12924226%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Monoi%20et%20al.%22%2C%22parsedDate%22%3A%222026-01-20%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMonoi%2C%20A.%2C%20Endo%2C%20A.%2C%20Procter%2C%20S.%20R.%2C%20Leuba%2C%20S.%20I.%2C%20Flasche%2C%20S.%2C%20Jit%2C%20M.%2C%20%26amp%3B%20Maternal%20RSV%20Vaccine%20Benefit-Risk%20Advisory%20Group.%20%282026%29.%20The%20benefits%20and%20risks%20of%20maternal%20RSV%20vaccination%20on%20mortality%20in%20South%20Africa%3A%20A%20modeling%20study.%20%26lt%3Bi%26gt%3BPLOS%20Medicine%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B23%26lt%3B%5C%2Fi%26gt%3B%281%29%2C%20e1004625.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pmed.1004625%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pmed.1004625%26lt%3B%5C%2Fa%26gt%3B%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20benefits%20and%20risks%20of%20maternal%20RSV%20vaccination%20on%20mortality%20in%20South%20Africa%3A%20A%20modeling%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ayaka%22%2C%22lastName%22%3A%22Monoi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Akira%22%2C%22lastName%22%3A%22Endo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%20R.%22%2C%22lastName%22%3A%22Procter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sequoia%20I.%22%2C%22lastName%22%3A%22Leuba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%22%2C%22lastName%22%3A%22Flasche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Jit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Maternal%20RSV%20Vaccine%20Benefit-Risk%20Advisory%20Group%22%7D%2C%7B%22creatorType%22%3A%22editor%22%2C%22firstName%22%3A%22Annettee%22%2C%22lastName%22%3A%22Nakimuli%22%7D%5D%2C%22abstractNote%22%3A%22Background%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Maternal%20respiratory%20syncytial%20virus%20%28RSV%29%20vaccine%2C%20RSV%20prefusion%20F%20protein%20vaccine%20%28RSVpreF%20%28Abrysvo%29%29%2C%20was%20found%20to%20be%20safe%20and%20efficacious%20in%20the%20MATISSE%20trial.%20However%2C%20post-hoc%20stratified%20analyses%20identified%20an%20excess%20of%20preterm%20births%20in%20the%20intervention%20arm%20in%20two%20upper-middle-income%20countries%2C%20most%20prominently%20in%20South%20Africa.%20This%20study%20weighs%20the%20potential%20benefits%20and%20risks%20in%20mortality%20associated%20with%20maternal%20RSV%20vaccination%20in%20South%20Africa%2C%20assuming%20the%20increased%20risk%20of%20preterm%20births%20observed%20in%20the%20trial%20was%20caused%20by%20vaccination.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20and%20findings%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20compared%20the%20estimated%20RSV-associated%20infant%20deaths%20averted%20by%20vaccination%20%28benefits%29%20and%20neonatal%20mortality%20potentially%20associated%20with%20vaccine-associated%20risk%20in%20preterm%20birth%20%28risks%29%20in%20South%20Africa.%20The%20benefit%20model%20estimated%20the%20South%20African%20RSV%20disease%20burden%20in%202011%5Cu22122016%20and%20waning%20vaccine%20protection%20during%20infancy.%20The%20risk%20model%20estimated%20excess%20neonatal%20mortality%20using%20gestational%20age%20%28GA%29-specific%20mortality%20data%20from%20the%20Drakenstein%20Child%20Health%20Study%20and%20the%20GA-specific%20birth%20distribution%20in%20South%20Africa%20in%20the%20MATISSE%20trial%2C%20but%20did%20not%20incorporate%20the%20mortality%20risk%20found%20in%20the%20MATISSE%20vaccine%20trial%20in%20which%20no%20excess%20deaths%20occurred.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20benefit%20model%20estimated%20that%20vaccination%20would%20reduce%20RSV-associated%20infant%20deaths%20by%2031%20%2895%25%20credible%20interval%20%28Crl%29%3A%2027%2C%2035%29%20per%20100%2C000%20live%20births%20born%20to%20vaccinated%20mothers%20in%20South%20Africa.%20Using%20the%20number%20of%20infants%20born%20to%20mothers%20vaccinated%20at%2024%5Cu201336%20GA%20weeks%20in%20the%20MATISSE%20trial%2C%20if%20the%20association%20in%20South%20Africa%20between%20vaccination%20and%20preterm%20birth%20is%20actually%20causal%2C%20the%20risk%20model%20suggested%20that%20neonatal%20deaths%20would%20increase%20by%2044%20%2895%25CrI%3A%20%5Cu221243%2C%20210%29%2C%20totaling%201.4%20%2895%25CrI%3A%20%5Cu22121.4%2C%206.9%29%20excess%20neonatal%20deaths%20for%20every%20infant%20RSV%20death%20prevented.%20When%20this%20was%20changed%20to%20the%20number%20of%20infants%20born%20to%20mothers%20vaccinated%20at%2027%5Cu201336%20GA%20weeks%20in%20the%20MATISSE%20trial%2C%20the%20predicted%20risks%20dropped%20and%20in%2097%25%20of%20the%20simulations%20the%20benefits%20outweighed%20the%20risks.%20The%20outcome%20was%20sensitive%20to%20the%20GA%20window%20that%20we%20used%20to%20determine%20which%20infants%20to%20include%20in%20the%20analysis.%20The%20study%20was%20limited%20by%20only%20considering%20mortality%20associated%20with%20RSV%20disease%20and%20preterm%20birth.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20If%20RSVpreF%20increases%20preterm%20birth%20risk%2C%20and%20if%20this%20increases%20neonatal%20mortality%2C%20then%20the%20benefit-risk%20analysis%20failed%20to%20show%20that%20the%20direct%20benefits%20of%20vaccination%20in%20reducing%20RSV-associated%20infant%20mortality%20would%20substantially%20outweigh%20the%20risks%20of%20preterm%20birth-associated%20neonatal%20mortality%20in%20South%20Africa%20with%20vaccination%20from%2024%20GA%20to%2036%20GA%20weeks.%20There%20was%20large%20uncertainty%20in%20the%20analyses%20due%20to%20small%20numbers%20of%20preterm%20births.%20With%20vaccination%20from%2027%20GA%20weeks%2C%20the%20benefit-risk%20analysis%20favored%20vaccination.%20RSVpreF%20vaccination%20has%20the%20potential%20to%20be%20safe%20and%20effective%20when%20used%20from%20the%20third%20trimester.%22%2C%22date%22%3A%222026-1-20%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pmed.1004625%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdx.plos.org%5C%2F10.1371%5C%2Fjournal.pmed.1004625%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221549-1676%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222026-02-04T02%3A39%3A32Z%22%7D%7D%2C%7B%22key%22%3A%22ERFN6N9U%22%2C%22library%22%3A%7B%22id%22%3A12924226%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Domai%20et%20al.%22%2C%22parsedDate%22%3A%222026-01-08%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDomai%2C%20F.%20M.%2C%20Shrestha%2C%20D.%2C%20Shrestha%2C%20R.%20K.%2C%20Thimi%2C%20M.%2C%20Ntiamoah%2C%20D.%20O.%2C%20Hayashi%2C%20Y.%2C%20Smith%2C%20C.%2C%20Kubo%2C%20Y.%2C%20Yeung%2C%20S.%2C%20Suzuki%2C%20M.%2C%20Morimoto%2C%20K.%2C%20Ariyoshi%2C%20K.%2C%20%26amp%3B%20Dhoubhadel%2C%20B.%20G.%20%282026%29.%20Non-Vaccine%20Serotype%20Replacement%20and%20Subdominant%20Persistence%20of%20Vaccine%20Types%20in%20Nepalese%20Infants%20Following%20PCV10%20Introduction.%20%26lt%3Bi%26gt%3BVaccines%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B14%26lt%3B%5C%2Fi%26gt%3B%281%29%2C%2073.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fvaccines14010073%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fvaccines14010073%26lt%3B%5C%2Fa%26gt%3B%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Non-Vaccine%20Serotype%20Replacement%20and%20Subdominant%20Persistence%20of%20Vaccine%20Types%20in%20Nepalese%20Infants%20Following%20PCV10%20Introduction%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fleurette%20Mbuyakala%22%2C%22lastName%22%3A%22Domai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dhruba%22%2C%22lastName%22%3A%22Shrestha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raj%20Kumar%22%2C%22lastName%22%3A%22Shrestha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Monika%22%2C%22lastName%22%3A%22Thimi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Desmond%20Opoku%22%2C%22lastName%22%3A%22Ntiamoah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yumiko%22%2C%22lastName%22%3A%22Hayashi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chris%22%2C%22lastName%22%3A%22Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yoshinao%22%2C%22lastName%22%3A%22Kubo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shunmay%22%2C%22lastName%22%3A%22Yeung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Motoi%22%2C%22lastName%22%3A%22Suzuki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Konosuke%22%2C%22lastName%22%3A%22Morimoto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Koya%22%2C%22lastName%22%3A%22Ariyoshi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bhim%20Gopal%22%2C%22lastName%22%3A%22Dhoubhadel%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%5Cu00a0Streptococcus%20pneumoniae%20is%20a%20leading%20cause%20of%20child%20mortality%20in%20Nepal%20despite%20the%20introduction%20of%20the%2010-valent%20pneumococcal%20conjugate%20vaccine%20%28PCV10%29.%20Vaccine%20effectiveness%20is%20threatened%20by%20the%20emergence%20of%20non-vaccine%20serotypes%20%28NVTs%29%20and%20the%20multiple%20serotypes%20carriage%20which%20often%20fail%20to%20be%20detected%20by%20traditional%20methods.%20We%20aimed%20to%20study%20changes%20in%20serotype%20distribution%20before%20and%20after%20PCV10%20immunization%20among%20infants%2C%20including%20serotype%20dominance%20in%20Nepalese%20infants%20in%20the%20post-vaccine%20era.%20Methods%3A%20We%20enrolled%20infants%20in%20a%20longitudinal%20cohort%20study%20%282020%5Cu20132022%29%20conducted%20in%20Bhaktapur%2C%20Nepal.%20Nasopharyngeal%20swabs%20were%20collected%20before%20PCV10%20dose%201%20%286%20weeks%29%20and%20at%209%20and%2012%20months%20post-immunization.%20We%20used%20a%20sensitive%20nanofluidic%20qPCR%20platform%20to%20detect%20multiple%20serotypes%20and%20establish%20their%20hierarchy%20by%20quantifying%20the%20bacterial%20load%20of%20each%20strain.%20Inverse%20Probability%20Weighting%20%28IPW%29%20adjusted%20risk%20factor%20analysis%20was%20used%20to%20account%20for%20loss%20to%20follow-up.%20Results%3A%20PCV10%20successfully%20reduced%20vaccine-type%20%28VT%29%20carriage%2C%20declining%20sharply%20from%2032.8%25%20at%206%20weeks%20to%204.8%25%20at%2012%20months.%20VTs%20were%20pushed%20from%20being%20the%20dominant%20strain%20to%20occupying%20subdominant%20roles%20in%20co-colonization.%20Conversely%2C%20NVTs%20rapidly%20filled%20the%20vacated%20niche%2C%20showing%20a%20significant%20increase%20in%20their%20dominant%20status%20%28p%20%26lt%3B%200.001%29.%20The%20most%20common%20replacing%20NVTs%20that%20rose%20to%20dominance%20were%2035B%2C%2019A%2C%206C%5C%2F6D%2C%20and%2015B%5C%2F15C.%20Significant%20risk%20factors%20for%20carriage%20included%20older%20infancy%20%28aOR%203.4%2C%2095%25CI%3A%202.6%5Cu20134.5%20at%209%20months%29%2C%20a%20household%20kitchen%20in%20the%20living%20area%20%28aOR%201.4%2C%2095%25CI%3A%201.0%5Cu20131.9%29%2C%20and%20winter%20%28aOR%201.7%2C%2095%25CI%3A%201.5%5Cu20132.7%29%20and%20pre-monsoon%20seasons%20%28aOR%202.0%2C%2095%25CI%3A%201.5%5Cu20132.8%29.%20Conclusions%3A%20While%20PCV10%20reduced%20overall%20VT%20circulation%2C%20the%20persistence%20of%20VTs%20in%20subdominant%20niches%20creates%20a%20continuous%20reservoir%20for%20potential%20re-emergence%20and%20antibiotic%20resistance.%20This%20clear%20hierarchical%20shift%20in%20dominance%20towards%20NVTs%20underscores%20the%20urgent%20need%20for%20a%20public%20health%20strategy%20that%20includes%20the%20adoption%20of%20a%20higher-valent%20PCV%20to%20provide%20broader%20protection%2C%20and%20interventions%20targeting%20environmental%20risk%20factors%20are%20essential%20to%20sustain%20long-term%20reductions%20in%20pneumococcal%20colonization.%22%2C%22date%22%3A%222026-01-08%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3390%5C%2Fvaccines14010073%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2076-393X%5C%2F14%5C%2F1%5C%2F73%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222076-393X%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222026-02-04T02%3A39%3A05Z%22%7D%7D%5D%7D
Yoshikawa, R., Ishii, Y., Sano, N., & Yasuda, J. (2025). Remdesivir as a potent antiviral against prototype and current epidemic Oropouche virus strains (BeAn19991 and PE-IAM4637). Virus Research, 363, 199680. https://doi.org/10.1016/j.virusres.2025.199680
Sakurai, Y., Hirano, M., Okada, S., Kurosaki, Y., Yoshikawa, R., Barr, J. N., Hewson, R., Yoshii, K., & Yasuda, J. (2026). Identification of claramine and anidulafungin as entry inhibitors of Crimean–Congo hemorrhagic fever virus. Antiviral Research, 246, 106343. https://doi.org/10.1016/j.antiviral.2026.106343
Mogasale, V. V., John, J., Sahai, N., Ray, A., Farooqui, H. H., Mogasale, V., Dhoubhadel, B. G., Edmunds, W. J., Clark, A., & Abbas, K. (2026). Burden of typhoid fever and antimicrobial resistance in India (2023): a modelling study. The Lancet Regional Health - Southeast Asia, 44, 100714. https://doi.org/10.1016/j.lansea.2025.100714
Monoi, A., Endo, A., Procter, S. R., Leuba, S. I., Flasche, S., Jit, M., & Maternal RSV Vaccine Benefit-Risk Advisory Group. (2026). The benefits and risks of maternal RSV vaccination on mortality in South Africa: A modeling study. PLOS Medicine, 23(1), e1004625. https://doi.org/10.1371/journal.pmed.1004625
Domai, F. M., Shrestha, D., Shrestha, R. K., Thimi, M., Ntiamoah, D. O., Hayashi, Y., Smith, C., Kubo, Y., Yeung, S., Suzuki, M., Morimoto, K., Ariyoshi, K., & Dhoubhadel, B. G. (2026). Non-Vaccine Serotype Replacement and Subdominant Persistence of Vaccine Types in Nepalese Infants Following PCV10 Introduction. Vaccines, 14(1), 73. https://doi.org/10.3390/vaccines14010073
View all
PAGE TOP
Contact